Link Medicine Publications

Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease.

Liu, Z., Meray, R. K., Grammatopoulos, T. N., Fredenburg, R. A., Cookson, M. R., Liu, Y., Logan, T., Lansbury, P. T., Jr.
Proc Natl Acad Sci U S A.; 2009. Epub March 4.

Relevant Lansbury Laboratory Publications

Reversible monoubiquitination regulates the Parkinson disease-associated ubiquitin hydrolase UCH-L1.

Meray RK, Lansbury PT Jr.
J Biol Chem. 2007 Apr;282(14):10567-75. Epub 2007 Jan 26.

Substrate recognition and catalysis by UCH-L1.

Luchansky SJ, Lansbury PT Jr, Stein RL.
Biochemistry. 2006 Dec 12;45(49):14717-25.

A century-old debate on protein aggregation and neurodegeneration enters the clinic.

Lansbury PT, Lashuel HA.
Nature. 2006 Oct 19;443(7113):774-9. Review.

Improving synaptic function in a mouse model of AD.

Lansbury PT Jr.
Cell. 2006 Aug 25;126(4):655-7.

Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins?

Lashuel HA, Lansbury PT Jr.
Q Rev Biophys. 2006 May;39(2):167-201. Epub 2006 Sep 18. Review.

Structural basis for conformational plasticity of the Parkinson's disease-associated ubiquitin hydrolase UCH-L1.

Das C., Hoang Q.Q., Kreinbring C.A., Luchansky S.J., Meray R.K., Ray S.S., Lansbury P.T., Ringe D., and Petsko G.A.
Proc Natl Acad Sci U S A. 2006 Mar 13; [Epub ahead of print].

Back to the future: the 'old-fashioned' way to new medications for neurodegeneration.

Lansbury, P. T. Jr. Nature Reviews Neuroscience.
2004 5: S51–S57

Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy.

Cuervo, A.M., Stefanis, L., Fredenburg, R., Lansbury, P.T., and Sulzer, D. Science.
2004 305(5688):1292-5.

Discovery of Inhibitors that Elucidate the Role of UCH-L1 Activity in the H1299 Lung Cancer Cell Line.

Liu, Y., Lashuel, H. A. et al. Chem Biol.
2003 10(9): 837-846.

The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect alpha-Synuclein Degradation and Parkinson's Disease Susceptibility.

Liu, Y., Fallon, L., et al. Cell.
2002 111(2): 209-18

Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.

Conway, K. A., Rochet, J. C. , et al. Science.
2001 294(5545): 1346-9.

Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease?

Goldberg, M. S., Lansbury, P. T. Jr. Nat Cell Biol.
2000 2(7): E115-9.


Overview Press Releases Media Coverage Publications	Link Medicine Publications Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease. Liu, Z., Meray, R. K., Grammatopoulos, T. N., Fredenburg, R. A., Cookson, M. R., Liu, Y., Logan, T., Lansbury, P. T., Jr. Proc Natl Acad Sci U S A.; 2009. Epub March 4. Relevant Lansbury Laboratory Publications Reversible monoubiquitination regulates the Parkinson disease-associated ubiquitin hydrolase UCH-L1. Meray RK, Lansbury PT Jr. J Biol Chem. 2007 Apr;282(14):10567-75. Epub 2007 Jan 26. Substrate recognition and catalysis by UCH-L1. Luchansky SJ, Lansbury PT Jr, Stein RL. Biochemistry. 2006 Dec 12;45(49):14717-25. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Lansbury PT, Lashuel HA. Nature. 2006 Oct 19;443(7113):774-9. Review. Improving synaptic function in a mouse model of AD. Lansbury PT Jr. Cell. 2006 Aug 25;126(4):655-7. Are amyloid diseases caused by protein aggregates that mimic bacterial pore-forming toxins? Lashuel HA, Lansbury PT Jr. Q Rev Biophys. 2006 May;39(2):167-201. Epub 2006 Sep 18. Review. Structural basis for conformational plasticity of the Parkinson's disease-associated ubiquitin hydrolase UCH-L1. Das C., Hoang Q.Q., Kreinbring C.A., Luchansky S.J., Meray R.K., Ray S.S., Lansbury P.T., Ringe D., and Petsko G.A. Proc Natl Acad Sci U S A. 2006 Mar 13; [Epub ahead of print]. Back to the future: the 'old-fashioned' way to new medications for neurodegeneration. Lansbury, P. T. Jr. Nature Reviews Neuroscience. 2004 5: S51–S57 Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Cuervo, A.M., Stefanis, L., Fredenburg, R., Lansbury, P.T., and Sulzer, D. Science. 2004 305(5688):1292-5. Discovery of Inhibitors that Elucidate the Role of UCH-L1 Activity in the H1299 Lung Cancer Cell Line. Liu, Y., Lashuel, H. A. et al. Chem Biol. 2003 10(9): 837-846. The UCH-L1 Gene Encodes Two Opposing Enzymatic Activities that Affect alpha-Synuclein Degradation and Parkinson's Disease Susceptibility. Liu, Y., Fallon, L., et al. Cell. 2002 111(2): 209-18 Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Conway, K. A., Rochet, J. C. , et al. Science. 2001 294(5545): 1346-9. Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Goldberg, M. S., Lansbury, P. T. Jr. Nat Cell Biol. 2000 2(7): E115-9.